UNITY Biotechnology EPS - Earnings per Share 2017-2025 | UNBX
UNITY Biotechnology eps - earnings per share from 2017 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| UNITY Biotechnology Annual EPS |
| 2024 |
$-1.54 |
| 2023 |
$-2.70 |
| 2022 |
$-4.68 |
| 2021 |
$-10.88 |
| 2020 |
$-18.45 |
| 2019 |
$-18.80 |
| 2018 |
$-27.00 |
| 2017 |
$-139.70 |
| 2016 |
$-114.20 |
| UNITY Biotechnology Quarterly EPS |
| 2025-03-31 |
$-0.43 |
| 2024-12-31 |
$-0.51 |
| 2024-09-30 |
$-0.38 |
| 2024-06-30 |
$-0.31 |
| 2024-03-31 |
$-0.34 |
| 2023-12-31 |
$-0.25 |
| 2023-09-30 |
$-1.01 |
| 2023-06-30 |
$-1.07 |
| 2023-03-31 |
$-0.37 |
| 2022-12-31 |
$1.38 |
| 2022-09-30 |
$-1.36 |
| 2022-06-30 |
$-1.90 |
| 2022-03-31 |
$-2.80 |
| 2021-12-31 |
$-1.81 |
| 2021-09-30 |
$-2.97 |
| 2021-06-30 |
$-3.20 |
| 2021-03-31 |
$-2.90 |
| 2020-12-31 |
$-3.55 |
| 2020-09-30 |
$-5.20 |
| 2020-06-30 |
$-3.80 |
| 2020-03-31 |
$-5.90 |
| 2019-12-31 |
$-3.70 |
| 2019-09-30 |
$-5.10 |
| 2019-06-30 |
$-5.60 |
| 2019-03-31 |
$-4.40 |
| 2018-12-31 |
$32.00 |
| 2018-09-30 |
$-4.50 |
| 2018-06-30 |
$-7.60 |
| 2018-03-31 |
$-46.90 |
| 2017-12-31 |
$-38.20 |
| 2017-09-30 |
$-36.30 |
| 2017-06-30 |
$-36.20 |
| 2017-03-31 |
$-29.00 |
| 2016-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.002B |
$0.000B |
|
UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.
|
